Etanercept is a fusion protein consisting of a recombinant tumour necrosis factor alpha receptor and the (Fc) constant region of human IgG1.
This molecule is able to bind both TNF-alpha and lymphotoxin (TNF-beta).
It is administered by twice weekly sub-cutaneous injection and is licensed for the treatment of rheumatoid arthritis and polyarticular juvenile idiopathic arthritis where treatment with other DMARDs including Methotrexate have failed.
Check the Summary of Product Characteristics before prescribing this drug.
Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page